Emerald Advisers LLC Has $42.90 Million Position in Insmed Incorporated (NASDAQ:INSM)

Emerald Advisers LLC increased its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 1.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 640,267 shares of the biopharmaceutical company’s stock after purchasing an additional 10,088 shares during the period. Insmed accounts for 1.8% of Emerald Advisers LLC’s holdings, making the stock its 7th biggest holding. Emerald Advisers LLC owned about 0.43% of Insmed worth $42,898,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of INSM. Victory Capital Management Inc. boosted its position in Insmed by 21.4% during the 4th quarter. Victory Capital Management Inc. now owns 18,797 shares of the biopharmaceutical company’s stock valued at $583,000 after acquiring an additional 3,311 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Insmed by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,128,436 shares of the biopharmaceutical company’s stock valued at $34,970,000 after purchasing an additional 28,629 shares during the last quarter. Calton & Associates Inc. bought a new position in Insmed in the fourth quarter worth about $248,000. QRG Capital Management Inc. purchased a new stake in shares of Insmed during the fourth quarter valued at about $246,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of Insmed by 5.4% in the 4th quarter. Principal Financial Group Inc. now owns 1,359,563 shares of the biopharmaceutical company’s stock valued at $42,133,000 after buying an additional 69,281 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently commented on INSM shares. Evercore ISI increased their target price on shares of Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. StockNews.com lowered Insmed from a “hold” rating to a “sell” rating in a report on Friday, August 9th. Morgan Stanley boosted their target price on Insmed from $60.00 to $85.00 and gave the stock an “overweight” rating in a research note on Friday, July 12th. Truist Financial decreased their price target on Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Wells Fargo & Company boosted their price target on Insmed from $55.00 to $77.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 29th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.19.

Insmed Stock Down 2.6 %

NASDAQ:INSM opened at $71.04 on Friday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The company’s fifty day moving average price is $73.85 and its 200-day moving average price is $48.74. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The firm has a market capitalization of $10.56 billion, a P/E ratio of -13.58 and a beta of 1.11.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. The business’s revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.78) EPS. As a group, equities research analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.